新疫苗引入成本预测的系统综述
该系统综述检索四个引擎1999年至2022年6月15日的文献,纳入171篇新疫苗成本预测研究,发现84%的成本预测属于成本效果分析,最常见成本数据来源为二手国家信息(43%),19%的研究未纳入疫苗递送成本,约半数仅计算疫苗接种成本,结论认为新疫苗引入的总成本常被低估。
要点
- 84%的成本预测是成本效果分析的一部分,最常见数据来源为二手国家信息(43%)。
- 19%的研究未纳入疫苗递送成本,纳入者中约半数仅计算疫苗接种成本(50%)。
- 作者建议指南和期刊推荐作者纳入更广泛的疫苗递送成本。
核心结论
- 半数新疫苗引入的经济学评价仅纳入部分疫苗递送成本,总成本常被低估。
- 作者建议经济学评价指南和期刊推荐作者纳入更广泛的疫苗递送成本。
研究设计与样本
- 系统检索PubMed、Cochrane Open Access、Mendeley和Google Scholar四个引擎,纳入1999年至2022年6月15日发表的新疫苗成本预测文章,按PRISMA 2020流程图分析。
- 共纳入171篇文章。
主要发现
- 半数文章来自高收入国家(50%),大多数成本预测是成本效果分析的一部分(84%)。
- 最常见成本数据来源为二手国家信息(43%),其次为作者假设(17%)、二手国际信息(14%)和原始数据收集(7%)。
- 19%的研究未在成本估计中纳入疫苗递送成本。
- 纳入二手疫苗递送成本的研究中,约半数仅计算疫苗接种成本(50%),35%纳入增量系统成本,15%利用成分数据。
- 三分之二的研究旨在为决策者提供引入疫苗的成本效果或成本效益信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A recent review of guidance documents on vaccine delivery costing revealed current guidance on cost projections for new vaccine introduction has gaps on methods of sampling, data collection and analysis. In preparation for updating the respective guidance, this systematic review was undertaken to qualitatively assess methodologies used in new vaccine cost projection studies. This will inform researchers and stakeholders about the methods of new vaccine introduction cost projections for strategic directions in countries where cost data are not available. METHODS: We systematically searched four search engines (PubMed, Cochrane Open Access, Mendeley and Google Scholar) for articles on cost projections for new vaccines published between 1999 and 15 June 2022. We developed inclusion and exclusion criteria for the selection of articles and analyzed the results using a PRISMA 2020 flow diagram. RESULTS: Out of 1,108 articles identified, 171 met the criteria for inclusion in the study. Half of the articles were from high-income countries (50%), and most cost projections were part of cost-effectiveness analysis (84%). The most common source of cost data was secondary national information (43%), followed by author's assumptions (17%), secondary international information (14%), and primary data collection (7%). 19% of studies didn't include costs to deliver vaccines in their cost estimation. Among studies that included secondary vaccine delivery costs, approximately half only calculated vaccine administration costs (50%), while 35% included incremental system costs and 15% utilized ingredients data. Two thirds of the studies were conducted to inform policymakers of the cost-effectiveness or cost-benefit of introducing the vaccine. CONCLUSIONS: Half of the economic evaluations on new vaccine introductions only included partial vaccine delivery costs. Thus, total costs of vaccine introduction were often being underestimated in economic evaluations. This suggests that guidelines on economic evaluations and journals should recommend that authors include more extensive vaccine delivery costs in their studies.
引用
- Levin A, Yeung KHT, Hutubessy R, et al. Systematic review of cost projections of new vaccine introduction. Vaccine. 2024. PMID: 38278630. doi:10.1016/j.vaccine.2024.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。